NCT05683171View on ClinicalTrials.gov

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Lymphoma

Interventions

DRUG

Rituximab

Given by IV (vein)

DRUG

Lenalidomide

Given by PO

DRUG

Valemetostat

Given by PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Daiichi Sankyo

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER